NicOx SA

275 articles about NicOx SA

• Nicox’s Partner Ocumension Therapeutics Receives Priority Review Status for ZERVIATE New Drug Application in China

  4/28/2023

  Nicox SA announced that the New Drug Application for approval to commercialize ZERVIATE®, 0.24%, submitted in China by its exclusive Chinese partner, Ocumension Therapeutics, has been included in the priority review and approval process of National Medical Products Administration of the People’s Republic of China.

• Transfer of Nicox’s shares to Euronext Growth Paris effective on April 28, 2023

  4/26/2023

  Nicox SA announced that the transfer of the listing of the securities issued by the Company from the Euronext Paris regulated market to the Euronext Growth Paris multilateral trading facility, will be effective as from the trading session of April 28, 2023.

• New Data on Two Nicox’s Assets, NCX 470 and NCX 1728, Presented at ARVO 2023

  4/26/2023

  Nicox SA announced that studies highlighting nonclinical data on NCX 470 and NCX 1728 have been presented at the Association for Research in Vision and Ophthalmology Annual Meeting 2023 being held April 23-27, 2023 in New Orleans, LA, United States.

• Nicox Provides First Quarter 2023 Financial and Business Highlights

  4/19/2023

  Nicox SA, an international ophthalmology company, provided financial and business highlights for the first quarter 2023 for Nicox SA and its subsidiaries.

• Additional Future Royalty Revenue Stream for Nicox from 2024 following New Drug Application Submission for ZERVIATE in China

  4/14/2023

  Nicox SA, an international ophthalmology company, announced that its exclusive Chinese partner, Ocumension Therapeutics, has submitted a New Drug Application for approval to commercialize ZERVIATE®, 0.24%, in China, for ocular itching associated with allergic conjunctivitis.

• Nicox Announces Presentations of Additional NCX 470 Data at the Upcoming World Glaucoma Congress

  3/21/2023

  Nicox SA, an international ophthalmology company, announced presentations of additional NCX 470 data at the 10th World Glaucoma Congress which will be held from June 28 to July 1st, 2023 in Rome, Italy.

• Nicox Reports 2022 Financial Results and Updates Key Future Milestones

  3/20/2023

  Nicox SA, an international ophthalmology company, announced the financial and operating results for Nicox and its subsidiaries for the year ended December 31, 2022, as approved by the Board of Directors on March 17, 2023, and updated key future milestones.

• Nicox to Present at Upcoming Scientific Conferences

  3/3/2023

  Nicox SA, an international ophthalmology company, announced a number of presentations at key ophthalmology conferences including the American Glaucoma Society Annual Meeting 2023 and the Association for Research in Vision and Ophthalmology Annual Meeting 2023.

• Nicox to Participate in Financial, Pharmaceutical Industry and Scientific Events in H1 2023

  1/24/2023

  Nicox SA, an international ophthalmology company, that members of the management team will participate in the following financial, pharmaceutical industry and scientific conferences in Europe and U.S. in the coming months:.

• Nicox Provides Fourth Quarter 2022 Financial Highlights

  1/18/2023

  Nicox SA, an international ophthalmology company, provided financial highlights for the fourth quarter 2022 for Nicox SA and its subsidiaries.

• Nicox Announces Proposed Move to Euronext Growth Paris

  1/9/2023

  Nicox SA announced its intention to move its listing from the Euronext Paris regulated market to Euronext Growth Paris and convened for this purpose an ordinary shareholder meeting on Tuesday February 14, 2023 at 2:00 pm CEST in the offices of BuroClub - Drakkar 2 - Bâtiment D - 2405 route des Dolines - 06560 Valbonne - France.

• Nicox Outlines Future Development and Partnering Plans for NCX 470 in Glaucoma

  11/7/2022

  Nicox SA, an international ophthalmology company, announced future development and partnering plans for NCX 470, a novel nitric oxide -donating bimatoprost eye drop, currently in Phase 3 development for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

• Nicox Reports Achieving Primary Objective in Mont Blanc, the First Phase 3 Glaucoma Trial for NCX 470

  10/31/2022

  Nicox SA, an international ophthalmology company, announced that once daily dosing of NCX 470 0.1% met the primary objective of non-inferiority in lowering intraocular pressure compared to the standard of care, latanoprost 0.005%, in the 691-patient Mont Blanc Phase 3 clinical trial in patients with open-angle glaucoma or ocular hypertension.

• Nicox Provides Third Quarter 2022 Financial and Business Highlights

  10/19/2022

  Nicox SA, an international ophthalmology company, provided financial and business highlights for the third quarter 2022 for Nicox SA and its subsidiaries and confirmed timing for the upcoming NCX 470 Mont Blanc Phase 3 clinical trial milestone.

• Nicox Announces Last Patients Complete Final Visit in NCX 470 Phase 3 Mont Blanc Glaucoma Trial

  9/19/2022

  Nicox SA, an international ophthalmology company, announced that the last patients completed their final visit in the Mont Blanc Phase 3 clinical trial of NCX 470 0.1% for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

• Nicox Provides First Half 2022 Business Update and Financial Results

  9/16/2022

  Nicox SA, an international ophthalmology company, provided business and financial results for Nicox SA and its subsidiaries for the first half of 2022.

• Nicox Appoints Jean-Francois Labbé as Chairman of the Board of Directors

  7/29/2022

  Nicox SA, an international ophthalmology company, announced that Jean-Francois Labbé, a Board member of Nicox SA, has been appointed as Chairman of the Nicox Board of Directors, effective July 28, 2022.

• Nicox Provides Second Quarter 2022 Financial and Business Highlights

  7/20/2022

  Nicox SA, an international ophthalmology company, provided financial and business highlights for second quarter 2022 for Nicox SA and its subsidiaries and updated on key upcoming milestones.

• Nicox Announces Publication of NCX 470 Results Demonstrating Improvements to Ocular Hemodynamics and Retinal Cell Physiology

  7/7/2022

  Nicox SA announced that the results from studies on the beneficial effects of NCX 470 in a nonclinical model of endothelin-1 -induced ischemia/reperfusion damage of the optic nerve head and retina have been published online in the peer-reviewed Journal of Ocular Pharmacology and Therapeutics.

• Nicox Accelerates Topline Results from NCX 470 Mont Blanc Phase 3 Glaucoma Trial to November 2022

  6/3/2022

  Nicox SA, an international ophthalmology company, announced that it has closed screening for additional patients in its Phase 3 Mont Blanc clinical trial of NCX 470 0.1% in patients with open-angle glaucoma or ocular hypertension.